Market Overview

Deutsche Bank Comments On Stryker Following Solid Earnings Report


Stryker's (NYSE: SYK) 1Q sales were in line with Consensus at $2.0B, up 12% reported and 10% ex-FX. Underlying hip and knee sales were below Deutsche Bank's estimate and likely the Street. However, MedSurg made up the difference. After adjusting for acquisitions and FX, sales were up just 4%--far from an impressive quarter but likely in line with the broader MedTech market. EPS rose 12.5% to $0.90 and were $0.01 ahead. Given the stock's relative premium valuation, Deutsche Bank sees the stock as fully valued and as it maintains a Hold and $61 PT.

Commentary suggests price stability and incrementally better mix better thus absent major market share movements from Zimmer and S&N unit volumes decelerated. While Deutsche Bank believes the volumes will recover, it thinks a recovery is farther off than the market expects and the magnitude may also be less as we expect net price/mix to remain negative.

Orthopedic sales were weaker though sales of MedSurg were better. However, net/net organic sales were up just 4% in the quarter. Total company pricing was down 1.9%, which was better than the 2.1% in 4Q though Deutsche Bank chalks it up to a greater MedSurg mix which has better pricing dynamics rather than a sign that ortho pricing is improving.

SYK closed Tuesday at $61.10


Related Articles (SYK)

View Comments and Join the Discussion!

Posted-In: Deutsche BankAnalyst Color Analyst Ratings

Latest Ratings

VOYAPiper SandlerMaintains58.0
PRUPiper SandlerMaintains64.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at